MNPR - strong-quarter-performance-amidst-negative-roi-and-roe

Deep-Dive Due Diligence AI Generated Report on Monopar Therapeutics Inc. Common Stock (MNPR)

Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.

These reports are generated using OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.

Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.

MNPR_OUT_1 [2025-03-19 14:16:15 -0400] 2249 Bytes | 633 tokens | Cum: 633 tkns (7.91% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Monopar Therapeutics (MNPR) which is at 39.935 up from 34.37. So, I pulled together a bunch of data for you to look over real fast. It's still early, 02:16:13 PM on Wednesday March 19, 2025 ET (UTC-0400). So, what's the verdict? You're the expert!

Here's the first list of news for Monopar Therapeutics:

C1 - Feb-03-25 07:22PM - Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025
C2 - Jan-23-25 01:10PM - Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
C3 - Jan-23-25 01:10PM 07:06AM - Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright
C4 - Dec-31-24 02:36AM - These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year Heres What Analysts Expect in 2025
C5 - Dec-20-24 09:00AM - Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
C6 - Dec-05-24 04:21PM - Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
C7 - Dec-03-24 08:00AM - Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
C8 - Nov-08-24 08:00AM - Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Monopar Therapeutics (MNPR)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Monopar Therapeutics.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

MNPR_IN_2 [2025-03-19 14:16:16 -0400] 2 Bytes | 2 tokens | Cum: 635 tkns (7.94% of 8k)
==========================================================================

MNPR_OUT_3 [2025-03-19 14:16:23 -0400] 973 Bytes | 266 tokens | Cum: 901 tkns (11.26% of 8k)
==========================================================================

Showing C3 (chunk 1 of 2): C3:
**Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright**
Date: Jan-23-25 01:10PM 07:06AM
Source: (TipRanks)
URL: https://finance.yahoo.com/news/monopar-therapeutics-price-target-raised-120616887.html

H.C. Wainwright raised the firm’sprice targeton Monopar Therapeutics (MNPR) to $40 from $22 and keeps a Buy rating on the shares. The firm expects ALXN-1840 to reach the market in the U.S. in late-2025 or early-2026, earlier than its previous estimate of the second half of 2025, and reach peak sales of $425M by 2033, up from a previous estimate of $272M.

FollowTipRanks' Top Wall Street Analyststo uncover their success rate and average return.

Join thousands of data-driven investors – Build yourSmart Portfoliofor personalized insights.

Published first onTheFly– the ultimate source for real-time, market-moving breaking financial news.Try Now>>

Monopar Therapeuti

-- More? (MOR) or Next section? (NEX)

MNPR_IN_4 [2025-03-19 14:16:23 -0400] 415 Bytes | 109 tokens | Cum: 1010 tkns (12.62% of 8k)
==========================================================================

H.C. Wainwright has increased its price target for Monopar Therapeutics (MNPR) from $22 to $40 and maintains a Buy rating for the shares. The firm predicts ALXN-1840 will hit the U.S. market in late 2025 or early 2026, which is earlier than its previous forecast for the second half of 2025. It also forecasts the drug to reach peak sales of $425M by 2033, a significant increase from the earlier estimate of $272M.

MNPR_OUT_5 [2025-03-19 14:16:24 -0400] 687 Bytes | 199 tokens | Cum: 1209 tkns (15.11% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T08:36:31Z - Piper Sandler Assumes Monopar Therapeutics (MNPR) at Overweight...
A2 - 2025-03-17T01:41:23Z - Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Growth in Short Interest...
A3 - 2025-03-04T09:57:14Z - Monopar Therapeutics: Strong Data, But There Are Risks (NASDAQ:MNPR)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MNPR_IN_6 [2025-03-19 14:16:24 -0400] 2 Bytes | 2 tokens | Cum: 1211 tkns (15.14% of 8k)
==========================================================================

MNPR_OUT_7 [2025-03-19 14:16:30 -0400] 699 Bytes | 199 tokens | Cum: 1410 tkns (17.62% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
**Piper Sandler Assumes Monopar Therapeutics (MNPR) at Overweight**Date: 2025-03-19Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/Analyst+Comments/Piper+Sandler+Assumes+Monopar+Therapeutics+%28MNPR%29+at+Overweight/24519545.htmlPiper Sandler analyst Biren Amin assumes coverage on Monopar Therapeutics (NASDAQ: MNPR) with a Overweight rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

-- More? (MOR) or Next section? (NEX)

MNPR_IN_8 [2025-03-19 14:16:30 -0400] 535 Bytes | 112 tokens | Cum: 1522 tkns (19.02% of 8k)
==========================================================================

The information provided states that Piper Sandler, through its analyst Biren Amin, has assumed coverage on Monopar Therapeutics (NASDAQ: MNPR), a company traded on the NASDAQ. Piper Sandler's stance is an Overweight rating, indicating that they believe the stock will outperform the average return of the market over the next 12 months. However, the specific price target is not mentioned in the provided text. This information is important for investors who are considering whether to buy, hold, or sell Monopar Therapeutics' shares.

MNPR_OUT_9 [2025-03-19 14:16:31 -0400] 884 Bytes | 287 tokens | Cum: 1809 tkns (22.61% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-11-08T13:00:00Z - Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
B2 - 2024-10-29T01:15:00Z - Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
B3 - 2024-06-25T12:00:00Z - Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
B4 - 2024-06-11T11:30:00Z - Monopar and NorthStar Amend & Extend Collaboration
B5 - 2024-05-24T12:00:00Z - Monopar Announces CFO Succession
B6 - 2024-05-17T13:55:03Z - Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MNPR_IN_10 [2025-03-19 14:16:31 -0400] 2 Bytes | 2 tokens | Cum: 1811 tkns (22.64% of 8k)
==========================================================================

MNPR_OUT_11 [2025-03-19 14:16:41 -0400] 626 Bytes | 168 tokens | Cum: 1979 tkns (24.74% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/11/08/2977596/0/en/Monopar-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Recent-Developments.htmlMonopar Therapeutics has in-licensed ALXN-1840, a late-stage drug candidate for Wilson disease, from Alexion, AstraZeneca Rare Disease. The company also has two novel radiopharma clinical trials active and enrolling patients with advanced solid cancers.

-- More? (MOR) or Next section? (NEX)

MNPR_IN_12 [2025-03-19 14:16:41 -0400] 1242 Bytes | 229 tokens | Cum: 2208 tkns (27.60% of 8k)
==========================================================================

As a financial analyst, you may be interested in Monopar Therapeutics' recent activities. The company has in-licensed a late-stage drug candidate, ALXN-1840, for Wilson disease from Alexion, AstraZeneca Rare Disease. This could potentially open up new revenue streams for the company and might have a positive impact on its financial performance if the drug is approved and reaches the market.

Furthermore, Monopar Therapeutics is conducting two active clinical trials for patients with advanced solid cancers. This indicates that the company is continuously investing in research and development, which is crucial for growth in the pharmaceutical industry.

However, it's important to note that conducting clinical trials and in-licensing drug candidates involve significant costs and risks. These activities will impact the company's financials, and there is also a risk that these investments may not yield the expected returns if the drug candidates fail to get regulatory approval or do not perform well in the market.

Therefore, while these developments could potentially improve the company's future earnings, it is also necessary to consider the associated risks when evaluating the company's financial performance and prospects.

MNPR_OUT_13 [2025-03-19 14:16:43 -0400] 267 Bytes | 68 tokens | Cum: 2276 tkns (28.45% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

MNPR_IN_14 [2025-03-19 14:16:43 -0400] 7 Bytes | 3 tokens | Cum: 2279 tkns (28.49% of 8k)
==========================================================================

Sure, I

MNPR_OUT_15 [2025-03-19 14:16:56 -0400] 4498 Bytes | 1204 tokens | Cum: 3483 tkns (43.54% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: Monopar Therapeutics (MNPR) by Tsuchimoto Kim R (Unknown Title) on 2025-03-04
- Stock Options: 11365 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by Talukdar Lavina (Unknown Title) on 2025-03-04
- Stock Options: 5683 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by Anderson Raymond (Unknown Title) on 2025-03-04
- Stock Options: 11365 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by KLAUSNER ARTHUR J (Unknown Title) on 2025-03-04
- Stock Options: 11365 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by STARR CHRISTOPHER M (Unknown Title) on 2025-03-04
- Stock Options: 11365 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by Cittadine Andrew (Chief Operating Officer) on 2025-03-04
- Stock Options: 43445 shares at $0 (D)
- Restricted Stock Units: 40581 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by Robinson Chandler (Chief Executive Officer) on 2025-03-04
- Common Stock: 6002 shares at $N/A (D)
- Common Stock: 1759 shares at $31.7 (D)
- Stock Options: 85759 shares at $0 (D)
- Restricted Stock Units: 79899 shares at $0 (D)
- Restricted Stock Units: 6002 shares at $0 (D)

No transactions recorded.

Inside Trans: Monopar Therapeutics (MNPR) by Vu Quan Anh (Chief Financial Officer) on 2025-03-03
- Stock Options: 25000 shares at $0 (D)

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

MNPR_IN_16 [2025-03-19 14:16:56 -0400] 1610 Bytes | 339 tokens | Cum: 3822 tkns (47.77% of 8k)
==========================================================================

Based on the given metrics, the company has shown a strong performance over the quarter with a 52.96% increase. However, the company's return on equity (ROE) and return on investment (ROI) are both negative, indicating the company is not generating a profit on the money shareholders have invested.

The company's Relative Strength Index (RSI) is 58.49, which is slightly above the neutral point, indicating a recent upward trend in price. The Average True Range (ATR) is 4.26, suggesting that the stock has been relatively volatile. The stock's price of 38.82 is higher than the previous close of 34.37, indicating a recent upward trend.

Furthermore, the company has a target price of 56.00, which indicates potential for future growth. However, the negative earnings per share (EPS) surprise of 62.81% could potentially be a point of concern for investors.

Looking at insider transactions, there have been several stock option grants at a price of $0, which could indicate optimistic future expectations from the insiders. However, no sales of these shares have been recorded, which could suggest that insiders are holding onto their shares in anticipation of further price appreciation.

In summary, while the company has demonstrated strong recent performance and insider confidence, the negative ROE, ROI, and EPS surprise may be potential red flags for investors. It's essential to consider these factors in the context of the company's overall financial health and market conditions.

MARKET_SCORE[65]
PRICE_TARGET[$45.00]

AI_RPT_HEADLINE: "Strong Quarter Performance Amidst Negative ROI and ROE"

MNPR_OUT_17 [2025-03-19 14:16:57 -0400] 561 Bytes | 131 tokens | Cum: 3953 tkns (49.41% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

MNPR_IN_18 [2025-03-19 14:16:57 -0400] 31 Bytes | 7 tokens | Cum: 3960 tkns (49.50% of 8k)
==========================================================================

-> X6 <- More financial metrics

MNPR_IN_19 [2025-03-19 14:16:58 -0400] 126 Bytes | 29 tokens | Cum: 3989 tkns (49.86% of 8k)
==========================================================================

====================================
[2025-03-19 11:16:58] # Analysis Completed
Elapsed Time: 45.21 seconds